- Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
- Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
- Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
- Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
- Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
- Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
More ▼
Key statistics
On Wednesday, Alto Neuroscience Inc (ANRO:NYQ) closed at 11.62, 23.62% above the 52 week low of 9.40 set on Jun 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.03 |
---|---|
High | 11.69 |
Low | 10.94 |
Bid | 11.10 |
Offer | 11.78 |
Previous close | 11.10 |
Average volume | 229.69k |
---|---|
Shares outstanding | 26.88m |
Free float | 23.36m |
P/E (TTM) | -- |
Market cap | 312.39m USD |
EPS (TTM) | -1.90 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 22:00 BST.
More ▼